Qiagen N.V. (NYSE: QGEN)
Health Care · Life Sciences Tools & Services · NL
$45.38
+1.91% today · -8.1% 1Y
Qiagen N.V. (NYSE: QGEN) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $9.38B and employs 5,500 people.
Over the last twelve months the share price has lost 8.1%, trading between 32.53 and 57.82.
Tweenvest scores Qiagen N.V. across four factors: quality 80/100, value 63/100, growth 26/100, dividend 91/100. Its strongest factor is dividend.
QGEN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.38B
- Revenue (TTM)
- $2.10B
- P/E
- 23.07
- EPS
- 1.97
- Dividend yield
- 6.20%
- Beta (5Y)
- 0.61
- 52-week high
- $57.82
- 52-week low
- $32.53
- Avg volume (3M)
- —
- Shares outstanding
- 206.80M
- Employees
- 5,500
- Next earnings
- —
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
- ISIN
- NL0015002SN0
- Founded
- 1984
- Listed since
- Jun 28, 1996
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Avantor, Inc.NYSE: AVTR | $10.60B | $15.67 | +1.82% |
| 10x Genomics, Inc.NasdaqGS: TXG | $10.51B | $80.65 | +4.36% |
| Repligen CorporationNasdaqGS: RGEN | $9.81B | $173.88 | +6.13% |
| Bio-Rad Laboratories, Inc.NYSE: BIO | $9.78B | $366.16 | +1.60% |
| Bruker CorporationNasdaqGS: BRKR | $8.96B | $58.84 | +1.59% |
| Bachem Holding AGSWX: BANB | $7.22B | CHF80.05 | +2.76% |
| Hangzhou Tigermed Consulting Co., LtdSZSE: 300347 | $6.56B | CN¥55.18 | -5.51% |
| Joinn Laboratories(China)Co.,Ltd.SHSE: 603127 | $5.35B | CN¥52.60 | +6.69% |
Figures last refreshed Oct 11, 2026.